Bio-IGRT

Summary

Image-guided radiotherapy (IGRT) represents a novel method to precisely deliver radiation to tumours while sparing surrounding normal tissues. Integration of biological imaging using PET or MRI appears to be a promising concept to improve radiotherapy (Bio-IGRT). For this it is essential that biological imaging provides radiobiologically relevant information. Preclinical and clinical investigations into validation of PET tracers and MR methods in the context of curative radiotherapy and of concepts for biology-based escalation of radiation dose as well as other therapeutic interventions are an important task for further cancer research.

Zusammenfassung

Die bildgestützte Strahlentherapie (IGRT) ist eine neue Methode zur exakten Tumorbestrahlung und gleichzeitigen Schonung des umliegenden Normalgewebes. Ein vielversprechendes Konzept zur weiteren Verbesserung der IGRT stellt die Einbeziehung biologischer Bildgebung mittels PET und MRT dar (Bio-IGRT). Hierbei ist von besonderer Bedeutung, dass strahlenbiologisch relevante Eigenschaften des Tumors abgebildet werden. Präklinische und klinische Untersuchungen zur Validierung von PET-Tracern im Kontext der kurativen Strahlentherapie und von verschiedenen Konzepten der biologisch-adaptierten Dosiseskalation sowie anderer therapeutischer Interventionen sind eine wichtige Aufgabe der onkologischen Forschung.

Keywords

Image-guided radiotherapy - biological factors of radiation resistance of tumours - radiation biology - hypoxia

Schlüsselwörter

Bild-gestützte Strahlentherapie - biologische Faktoren der Strahlenresistenz von Tumoren - Strahlenbiologie - Hypoxie

• Literatur

• 1 Baumann M, Krause M, Hill R. Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 2008; 8: 545-554.
• 2 Galvin JM, De Neve W. Intensity modulating and other radiation therapy devices for dose painting. J Clin Oncol 2007; 25: 924-930.
• 3 Horsman M, Wouters B, Joiner M, Overgaard J. The oxygen effect and fractionated radiotherapy. In: Joiner M, van der Kogel A. (eds) Basic Clinical Radiobiology. London: Hodder Arnold; 2009: 207-216.
• 4 Kaanders JH, Wijffels KI, Marres HA. et al. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res 2002; 62: 7066-7074.
• 5 Ling CC, Humm J, Larson S. et al. Towards multidimensional radiotherapy (MD-CRT). Int J Radiat Oncol Biol Phys 2000; 47: 551-560.
• 6 Overgaard J, Eriksen JG, Nordsmark M. et al. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer. Lancet Oncol 2005; 6: 757-764.
• 7 Rischin D, Hicks RJ, Fisher R. et al. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine. J Clin Oncol 2006; 24: 2098-2104.
• 8 Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 2004; 14: 198-206.
• 9 Yaromina A, Eckardt A, Zips D. et al. Core needle biopsies for determination of the microenvironment in individual tumours for longitudinal radiobiological studies. Radiother Oncol 2009; 92: 460-465.
• 10 Yaromina A, Krause M, Thames HD. et al. Pre-treatment number of clonogenic tumour cells and their radiosensitivity are major determinants of local tumour control after fractionated irradiation. Radiother Oncol 2007; 83: 304-310.
• 11 Yaromina A, Thames H, Zhou X. et al. Radiobiological hypoxia, histological parameters of tumour microenvironment and local tumour control after fractionated irradiation. Radiother Oncol 2010; 96: 116-122.
• 12 Zips D. Tumour growth and response to radiation. In: Joiner M, van der Kogel A. (eds) Basic clinical radiobiology. London: Hodder Arnold; 2009: 78-101.